Activation of soluble guanylyl cyclase with inhibi... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Activation of soluble guanylyl cyclase with inhibition of multidrug resistance protein inhibitor-4 (MRP4) as a new antiplatelet therapy

Full text
Author(s):
Mendes-Silverio, Camila B. [1] ; Lescano, Caroline H. [1] ; Zaminelli, Tiago [1] ; Sollon, Carolina [1] ; Anhe, Gabriel F. [1] ; Antunes, Edson [1] ; Monica, Fabiola Z. [1]
Total Authors: 7
Affiliation:
[1] Univ Campinas UNICAMP, Fac Med Sci, Dept Pharmacol, Sao Paulo - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Biochemical Pharmacology; v. 152, p. 165-173, JUN 2018.
Web of Science Citations: 3
Abstract

The intracellular levels of cyclic GMP are controlled by its rate of formation through nitric oxide-mediated stimulation of soluble guanylate cyclase (sGC) and its degradation by phosphodiesterases. Multidrug resistance protein 4 (MRP4) expressed in human platelets pumps cyclic nucleotides out of cells. In search for new anti platelet strategies, we tested the hypothesis that sGC activation concomitant with MRP4 inhibition confers higher antiplatelet efficacy compared with monotherapy alone. This study was undertaken to investigate the pharmacological association of the sGC activator BAY 60-2770 with the MRP4 inhibitor MK571 on human washed platelets. Collagen- and thrombin-induced platelet aggregation and ATP-release reaction assays were performed. BAY 60-2770 (0.001-10 mu M) produced significant inhibitions of agonist-induced platelet aggregation accompanied by reduced ATP-release. Pre-incubation with 10 mu M MK571 alone had no significant effect on platelet aggregation and ATP release, but it produced a left displacement by about of 10-100-fold in the concentration-response curves to BAY 60-2770. Pre-incubation with MK571increased and decreased, respectively, the intracellular and extracellular levels of cGMP to BAY 60-2770, whereas the cAMP levels remained unchanged. The increased VASP-serine 239 phosphorylation in BAY 60-2770-treated platelets was enhanced by MK571. In Fluo-4-loaded platelets, BAY 60-2770 reduced the intracellular Ca2 + levels, an effect significantly potentiated by MK571. Flow cytometry assays showed that BAY 60-2770 reduces the alpha IIb beta 3 integrin activation, which was further reduced by MK571 association. Blocking the MRP4-mediated efflux of cGMP may be a potential mechanism to enhance the antiplatelet efficacy of sGC activators. (AU)

FAPESP's process: 14/02130-1 - Role of insulin resistance in the pulmonary eosinophil recruitment in obese mice: anti-inflammatory and antioxidant actions of resveratrol
Grantee:Edson Antunes
Support Opportunities: Regular Research Grants